Children and Adults With Chordoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03910465|
Recruitment Status : Recruiting
First Posted : April 10, 2019
Last Update Posted : March 1, 2021
Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways. They hope this will help them design better future treatments and supportive care studies for this disease.
To learn more about chordoma by looking at its clinical course, how it appears on imagine scans, and how it responds to therapies and treatments.
People ages 2 and older with chordoma who are enrolled in NCI protocol 19-C-0016
Participants will be screened with their medical history.
Participants will have a visit to examine their disease. This will include:
- Physical exam
- Neurologic exam
- CT scan and MRI: Participants will lie on a table. The table will slide into a machine. The machine will take pictures of the body.
Participants will have other tests every 6-12 months:
- Smell test
- Surveys to assess their emotional, physical, and behavioral well-being and needs
- Cognitive function tests
Participants or their home doctors will be contacted every 6 12 months. They will be asked to provide information about their disease. This could include test results and imaging evaluations.
Some participants may be asked to come to the clinic for more visits.
|Condition or disease|
- Chordomas are a rare tumor with an incidence of 325 new cases per year in the United States. Pediatric chordomas are very rare and comprise only 5% of all chordoma cases.
- The standard therapy for localized primary or recurrent chordomas is surgical resection. However, complete surgical resection is often not possible due to the location of the
-For chordomas that cannot be surgically resected, treatment options are limited. Currently,
no standard therapy approach exists for recurrent chordomas. In addition, there are no FDA approved medical therapies for chordoma.
- The natural history of pediatric and adult chordoma is incompletely understood. Patients with chordoma seek expert advice in the management of their care.
- The NCI has basic and clinical expertise and research interest in chordoma. The planned natural history study as part of the NCI POB Rare Tumor Patient Engagement Network (RTPEN) will allow for comprehensive evaluation and recommendations to these patients while longitudinally collecting clinical, epidemiologic and biological data.
-To characterize the natural history of chordoma, including clinical presentation and patterns of disease progression.
- Subjects with histologically documented chordoma.
- Age greater than or equal to 2 years old
-This protocol is a subprotocol to protocol 19-C-0016: Natural History and Biospecimen
Acquisition Study for Children and Adults with Rare Solid Tumors . After enrollment on the master protocol and undergoing evaluations detailed, patients will be enrolled on this subprotocol specific for chordoma.
-Medical histories will be documented, and patients followed throughout the course of their disease, with particular attention to patterns of disease recurrence and progression, response to therapies, duration of responses and patient reported outcomes. Tumor growth rates will also be calculated throughout the course of the disease.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Natural History Study of Children and Adults With Chordoma|
|Actual Study Start Date :||April 16, 2019|
|Estimated Primary Completion Date :||December 31, 2029|
|Estimated Study Completion Date :||December 31, 2029|
Subjects with confirmed chordoma
- To characterize the natural history of chordoma, including clinical presentation and patterns of disease progression [ Time Frame: 10 years ]Natural history of chordoma, including clinical presentation and patterns of disease progression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03910465
|Contact: Barbara (BJ) Thomas, R.N.||(240) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Brigitte C Widemann, M.D.||National Cancer Institute (NCI)|